Login to Your Account


'An extremely debilitating disease'

LONDON - Eight years on from securing the first EMA approval for an autologous cell therapy, Tigenix NV has done it again, getting the nod for the first allogeneic adipose-derived stem cell therapy, Alofisel (Cx601, darvadstrocel).

more »


Analysis

The Good Pharma Scorecard (GPS) released last week by the not-for-profit Bioethics International contained surprisingly good news. Two companies – Johnson & Johnson (J&J) and Sanofi SA – of 11 ranked on overall clinical trial transparency, based on drugs approved in 2014, achieved scores of 100 percent, tying them at the top of the list. Four others – Abbvie Inc., Celgene Corp., Merck & Co. Inc. and Astrazeneca plc – scored at or above the industry median of 91 percent.

read more »

Opinion


Partners in Focus